Project: Every Child for Younger Patients With Cancer
Key facts
- Where
- Caguas és San Juan, Puerto RicoSee the 3 sites
Where in Puerto Rico
- HIMA San Pablo Oncologic HospitalCaguas, Puerto RicoNo longer taking part
- University Pediatric HospitalSan Juan, Puerto RicoTaking people
- San Jorge Children's HospitalSan Juan, Puerto RicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Children's Oncology Group
- Trial code
- NCT02402244
- Record updated
- 2026. augusztus 25.
- Original description
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.Read full original descriptionShow less
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Inclusion: Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem; Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority; Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:; All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one "1" (borderline), two "2" (carcinoma in situ) or three "3" (malignant); All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant; All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant; The following other benign/borderline conditions:; Mesoblastic nephroma; Teratomas (mature and immature types); Myeloproliferative diseases including transient myeloproliferative disease; Langerhans cell histiocytosis; Lymphoproliferative diseases; Desmoid tumors; Gonadal stromal cell tumors; Neuroendocrine tumors including pheochromocytoma; Melanocytic tumors, except clearly benign nevi; Ganglioneuromas; Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network [NCTN]) therapeutic study, for which there is a higher upper age limit; All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission; If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1.